Gender Differences in Perceptions of Psoriatic Arthritis Disease Impact, Management, and Physician Interactions: Results from a Global Patient Survey

Psoriatic Arthritis

Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies

Ther Adv Musculoskelet Dis

Kristensen LE, Tillett W, Nash P, Coates LC, Mease PJ, Ogdie A, Gisondi P, Ink B, Prickett AR, Bajracharya R, Taieb V, Lyris N, Lambert J, Walsh JA

doi: 10.1177/1759720X241288071

Rheumatoid Arthritis

Variability of Psoriatic Arthritis Impact of Disease questionnaire (PsAID12) thresholds in psoriatic arthritis: data from the ReFlaP study

Rheumatology (Oxford)

López-Medina C, Gorlier C, Orbai AM, Coates LC, Kiltz U, Leung YY, Palominos P, Cañete JD, Scrivo R, Balanescu A, Dernis E, Meisalu S, Ruyssen-Witrand A, Soubrier M, Aydin SZ, Eder L, Gaydukova I, Lubrano E, Kalyoncu U, Richette P, Husni ME, Smolen JS, de Wit M, Gossec L

doi: 10.1093/rheumatology/keaf002

Psoriatic Arthritis

Pain catastrophizing negatively impacts drug retention rate in patients with Psoriatic Arthritis and axial Spondyloarthritis: results from a 2-years perspective multicenter GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica) study

Arthritis Res Ther

Currado D, Saracino F, Ruscitti P, Marino A, Pantano I, Vomero M, Berardicurti O, Pavlych V, Di Vico C, Caso F, Costa L, Tasso M, Camarda F, Misceo F, De Vincenzo F, Corrado A, Arcarese L, Rigon A, Vadacca M, Corberi E, Kun L, Trunfio F, Pilato A, Lamberti L, Cantatore FP, Perosa F, Guggino G, Scarpa R, Cipriani P, Ciccia F, Giacomelli R, Navarini L

doi: 10.1186/s13075-024-03396-5

Rheumatoid Arthritis

Associations between loneliness, disease activity, and disease impact in inflammatory arthritis: A nationwide cross-sectional study among > 12,000 patients

Rheumatology (Oxford)

Vestergaard SB, Esbensen BA, Midtgaard J, Cromhout PF, Aadahl M, Glintborg B, de Thurah A

doi: 10.1093/rheumatology/keae471

Rheumatoid Arthritis

Impact of systemic inflammation and disease activity on the incidence of interstitial lung disease in patients with rheumatoid arthritis - a nested case-control study within the German biologics register RABBIT

Arthritis Res Ther

Ramien R, Rudi T, Alten R, Krause A, Schneider M, Schaefer M, Strangfeld A, Meissner Y

doi: 10.1186/s13075-024-03449-9

Psoriatic Arthritis

Bimekizumab Improves Patient-Reported Outcomes and Work Productivity in Patients with Psoriatic Arthritis: 1-Year Results from Two Phase 3 Studies

J Rheumatol

Gladman DD, Mease PJ, Gossec L, Husni ME, Gottlieb AB, Ink B, Bajracharya R, Coarse J, Lyris N, Lambert J, Tillett W

doi: 10.3899/jrheum.2024-0923

Juvenile Idiopathic Arthritis

Factors for Consideration by Pediatric Rheumatologists When Scoring the Physician Global Assessment (PhGA) of Disease Activity in Juvenile Idiopathic Arthritis: First Step Toward an Internal Consensus

Arthritis Care Res (Hoboken)

Tarkiainen M, Balay-Dustrude E, Consolaro A, Morgan EM, Ruperto N, Rypdal V, Backström M, Vähäsalo P, Gottlieb BS, Paediatric Rheumatology International Trials Organisation, and the Pediatric Rheumatology Care & Outcomes Improvement Network and the PhGA consensus task force, For the Pediatric Rheumatology European Society (PRES) JIA working party

doi: 10.1002/acr.25447

Rheumatoid Arthritis

A mobile app to support self-management and remotely monitor disease impact in rheumatoid arthritis: the randomised controlled AEGORA trial

Rheumatology (Oxford)

Doumen M, De Meyst E, Bertrand D, Pazmino S, Piessens M, Joly J, Devinck M, Westhovens R, Verschueren P

doi: 10.1093/rheumatology/keae638

Psoriatic Arthritis

Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial

RMD Open

McInnes IB, Sewerin P, Sharaf M, Efficace M, Lavie F, Zimmermann M, Coates LC

doi: 10.1136/rmdopen-2024-004494

Related content

Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies

Variability of Psoriatic Arthritis Impact of Disease questionnaire (PsAID12) thresholds in psoriatic arthritis: data from the ReFlaP study

Pain catastrophizing negatively impacts drug retention rate in patients with Psoriatic Arthritis and axial Spondyloarthritis: results from a 2-years perspective multicenter GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica) study

Associations between loneliness, disease activity, and disease impact in inflammatory arthritis: A nationwide cross-sectional study among > 12,000 patients

Impact of systemic inflammation and disease activity on the incidence of interstitial lung disease in patients with rheumatoid arthritis - a nested case-control study within the German biologics register RABBIT

Bimekizumab Improves Patient-Reported Outcomes and Work Productivity in Patients with Psoriatic Arthritis: 1-Year Results from Two Phase 3 Studies

Factors for Consideration by Pediatric Rheumatologists When Scoring the Physician Global Assessment (PhGA) of Disease Activity in Juvenile Idiopathic Arthritis: First Step Toward an Internal Consensus

A mobile app to support self-management and remotely monitor disease impact in rheumatoid arthritis: the randomised controlled AEGORA trial

Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial